Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020239687 - 18F-LABELED NOVEL TETRAZINES IMAGING PROBES FOR PRETARGETING IN PET IMAGING

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS

1. A 18F-labelled tetrazine formed by reacting a tetrazine with a 18F-labelled azide synthon, in which

said tetrazine is a compound according to any of structures 1-6:


and

said 18F-labelled azide synthon is a compound according to any of structures [18F]a, [18F]b, [18F]c:


2. A 18F-labelled tetrazine according to claim 1 , wherein the tetrazine is a compound according to structure 1 , 3 or 4 and the 18F-labelled azide synthon is a compound according to structure [18F]c, preferably the tetrazine is a compound according to structure 1 and the 18F-labelled azide synthon is a compound according to structure [18F]c.

3. A 18F-labelled tetrazine according to claim 1 or 2, wherein said reacting of tetrazine with a 18F-labelled azide synthon occurs by Cu-catalyzed azide-alkyne [3+2] cycloaddition (CuAAC).

4. Method of producing an image of an organ in an animal or human, comprising forming in the animal or human a product resulting from the biorthogonal ligation between i) a 18F-labelled tetrazine wherein said reacting of tetrazine with a 18F-labelled azide synthon occurs by Cu-

catalyzed azide-alkyne [3+2] cycloaddition (CuAAC) and ii) monoclonal antibodies (mAbs) modified with trans-cyclooctene (TCO).

5. Method according to claim 4, wherein the method is pretargeted immune-positron emission tomography (PET) imaging, by which said monoclonal antibodies (mAbs) modified with trans-cyclooctene (TCO) are provided to accumulate in a target tissue such as a tumor tissue prior to conducting said biorthogonal ligation with a 18F-labelled tetrazine.

6. Method according to claim 4 or 5, wherein the 18F-labelled tetrazine is formed by reacting a tetrazine with a 18F-labelled azide synthon, in which said tetrazine is a compound according to any of structures: 1 , 3 or 4, and said 18F-labelled azide synthon is a compound according to structure [18F]c, preferably the tetrazine is a compound according to structure 1 and the 18F-labelled azide synthon is a compound according to structure [18F]c.

7. Use of a 18F-labelled tetrazine according to any of claims 1-3 for imaging the accumulation of tumors.